These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 22901387

  • 1. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD, Fang F, Li JR, Du QR, Sun J, Gong HB, Zhu HL.
    Bioorg Med Chem Lett; 2012 Sep 15; 22(18):5870-5. PubMed ID: 22901387
    [Abstract] [Full Text] [Related]

  • 2. Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.
    Chilin A, Conconi MT, Marzaro G, Guiotto A, Urbani L, Tonus F, Parnigotto P.
    J Med Chem; 2010 Feb 25; 53(4):1862-6. PubMed ID: 20095624
    [Abstract] [Full Text] [Related]

  • 3. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT, Marzaro G, Urbani L, Zanusso I, Di Liddo R, Castagliuolo I, Brun P, Tonus F, Ferrarese A, Guiotto A, Chilin A.
    Eur J Med Chem; 2013 Sep 25; 67():373-83. PubMed ID: 23900004
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
    Hu S, Xie G, Zhang DX, Davis C, Long W, Hu Y, Wang F, Kang X, Tan F, Ding L, Wang Y.
    Bioorg Med Chem Lett; 2012 Oct 01; 22(19):6301-5. PubMed ID: 22959248
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS, Tanaka Y, Nabeyama W, Hatori M, Nakamura H.
    Bioorg Med Chem; 2010 Jan 15; 18(2):870-9. PubMed ID: 19969465
    [Abstract] [Full Text] [Related]

  • 6. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X, Lv Y, Liu P, Li Z, Hu L, Zeng C, Yang L.
    Bioorg Med Chem Lett; 2016 Mar 15; 26(6):1571-1575. PubMed ID: 26879314
    [Abstract] [Full Text] [Related]

  • 7. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
    Garofalo A, Goossens L, Lemoine A, Farce A, Arlot Y, Depreux P.
    J Enzyme Inhib Med Chem; 2010 Apr 15; 25(2):158-71. PubMed ID: 20222760
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
    El Ella DA, Saleh KA, Hassan M, Hamdy N, El-Araby ME, Abouzid KA.
    Arzneimittelforschung; 2012 Aug 15; 62(8):360-6. PubMed ID: 22723174
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT, Yuan TT, Liu HH, Chen SF, Wu YT.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6373-7. PubMed ID: 17889528
    [Abstract] [Full Text] [Related]

  • 10. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents.
    Lv PC, Li DD, Li QS, Lu X, Xiao ZP, Zhu HL.
    Bioorg Med Chem Lett; 2011 Sep 15; 21(18):5374-7. PubMed ID: 21802290
    [Abstract] [Full Text] [Related]

  • 11. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
    Chen L, Zhang Y, Liu J, Wang W, Li X, Zhao L, Wang W, Li B.
    Eur J Med Chem; 2017 Sep 29; 138():689-697. PubMed ID: 28711703
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors.
    Lv PC, Zhou CF, Chen J, Liu PG, Wang KR, Mao WJ, Li HQ, Yang Y, Xiong J, Zhu HL.
    Bioorg Med Chem; 2010 Jan 01; 18(1):314-9. PubMed ID: 19914835
    [Abstract] [Full Text] [Related]

  • 13. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors.
    Rao GW, Xu GJ, Wang J, Jiang XL, Li HB.
    ChemMedChem; 2013 Jun 01; 8(6):928-33. PubMed ID: 23640754
    [Abstract] [Full Text] [Related]

  • 14. Discovery of novel 4-anilinoquinazoline derivatives as potent inhibitors of epidermal growth factor receptor with antitumor activity.
    Xu YY, Li SN, Yu GJ, Hu QH, Li HQ.
    Bioorg Med Chem; 2013 Oct 01; 21(19):6084-91. PubMed ID: 23962660
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X, Peng T, Ji X, Li J, Tong L, Li Z, Yang W, Xu Y, Li M, Ding J, Jiang H, Xie H, Liu H.
    Bioorg Med Chem; 2013 Dec 15; 21(24):7988-98. PubMed ID: 24183742
    [Abstract] [Full Text] [Related]

  • 16. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J, Ren H, Zhao M, Chong Y, Zhao W, He Y, Zhao Y, Zhang H, Qi C.
    Eur J Med Chem; 2017 Sep 29; 138():669-688. PubMed ID: 28711702
    [Abstract] [Full Text] [Related]

  • 17. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase.
    Ban HS, Usui T, Nabeyama W, Morita H, Fukuzawa K, Nakamura H.
    Org Biomol Chem; 2009 Nov 07; 7(21):4415-27. PubMed ID: 19830290
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
    Ghorab MM, Alsaid MS, Soliman AM, Al-Mishari AA.
    J Enzyme Inhib Med Chem; 2018 Dec 07; 33(1):67-73. PubMed ID: 29098904
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.